Babyganics and Nikki Reed Launch ‘Oops! I Forgot It Again’ To Help Parents Prepare for Summer
Oops! I Forgot It Again stands open this weekend in New York and Los Angeles for parents to grab what they forgot to pack on their way out the door SAN FRANCISCO, May 31, 2024 /PRNewswire/ — Babyganics understands that there’s no such thing as perfect parenting. The process to get ready
Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders
VANCOUVER, BC, May 31, 2024 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assi
Discover the World expands relationship with South African Airways adding Key European Markets
SCOTTSDALE, Ariz., May 31, 2024 /PRNewswire/ — Under a newly announced agreement, Discover the World has been chosen to represent South African Airways (SAA) in the strategically important markets of the Nordics (Norway, Sweden, Finland, and Denmark), France, Spain, Switzerland, and Italy effe
Hamamatsu Photonics completes the acquisition of NKT Photonics A/S
BRIDGEWATER, N.J., May 31, 2024 /PRNewswire/ — Hamamatsu Photonics K.K. (Hamamatsu City, Japan) is delighted to announce the completion of the acquisition of NKT Photonics A/S. The Hamamatsu Photonics Group now possesses a very broad range of technologies in light sources, lasers, and detecto
RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC (“Bidco”) which is an Affiliate of K1 INVESTMENT MANAGEMENT, LLC (“K1”) as manager of K5 PRIVATE INVESTORS, L.P.
ANNOUNCEMENT REGARDING RULE 15 PROPOSALS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. MANHATTAN BEACH, Calif., June 01, 2024 /PRNewswire/ — On 24 May 2
Vivacelle Bio’s President and Chief Innovation Officer to Present Data Highlighting the Company’s Late-Stage Clinical Programs at the BIO International Convention 2024
Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions Vivacelle’s pipeline is led by VBI-S, a Phase 3-ready asset designated for the treatment of hypotension and hypovolemia in septic shock patients, and VBI-1, a Phase 2-ready candidate for hemorrhagic s
